Sustained-Release Nucleic Acid Formulations for Nerve Remyelination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective treatments for nerve damage, particularly demyelination due to conditions like Charcot-Marie-Tooth Disease, Guillain-Barre Syndrome, and diabetic neuropathy, by leveraging the regulatory functions of EGR2 and c-JUN transcription factors.
Innovation Solution
Formulations using nucleic acids, such as antisense RNA, are developed to modify EGR2 activity by activating H3K4me3 and repressing H3K27me3 histone markers, delivered via a polymeric gel and viral vector to promote chromatin remodeling and nerve re-myelination.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional treatment methods are used for nerve damage, then existing therapies are applied, but they are ineffective for demyelination conditions
Solution Approach 1:
The invention changes the therapeutic parameter from traditional symptomatic treatments to targeted gene regulation using antisense RNA. By modifying the molecular mechanism of action to specifically target EGR2 transcription factor and its associated histone markers (H3K4me3 activation and H3K27me3 repression), the treatment becomes effective for demyelination conditions where previous therapies failed.
2Speed
If nucleic acid formulations are delivered without sustained release mechanism, then immediate effect is achieved, but prolonged therapeutic action is not maintained
Solution Approach 1:
The invention introduces a polymeric gel formulation as an intermediary carrier system. This gel acts as a reservoir that slowly releases the nucleic acid therapeutic at the injection site, maintaining prolonged local concentrations of the antisense RNA without requiring repeated systemic administrations. The gel intermediary enables both sustained delivery and localized action.
3Productivity
If viral vectors are used for nucleic acid delivery, then efficient gene transfer is achieved, but potential immunogenicity and safety concerns arise
Solution Approach 1:
The invention employs local delivery of viral vectors directly to the nerve tissue at the site of injury rather than systemic administration. This localized approach concentrates the therapeutic effect where needed while minimizing exposure of other tissues to potential viral immunogenicity. The polymeric gel further confines the viral vector to the injection site, enhancing local transduction efficiency while reducing systemic side effects.
4Stability of the object's composition
If chromatin remodeling is not targeted, then general gene expression is maintained, but specific re-myelination pathways are not activated
Solution Approach 1:
The invention segments the chromatin remodeling target into specific transcriptional regulatory elements: activating H3K4me3 marks at the c-JUN promoter and repressing H3K27me3 marks at the EGR2 promoter. This segmented targeting of specific histone modifications at specific gene promoters enables selective activation of re-myelination pathways (c-JUN) while suppressing inhibitory pathways (EGR2), rather than global chromatin effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulations induce chromatin remodeling and re-myelination of damaged nerves, effectively treating conditions like Charcot-Marie-Tooth Disease, Guillain-Barre Syndrome, and diabetic neuropathy through sustained release and targeted gene regulation.
Implementation Method 1
EGR2-AS-RNA recruits chromatin remodeling complexes to inhibit EGR2 transcription after peripheral nerve injury
Implementation Method 2
EGR2-AS-RNA recruits chromatin modifying enzymes and histone marks on the promoters of EGR2 and c-JUN
Implementation Method 3
using a polymeric gel formulation to provide sustained release
Implementation Method 4
using a polymeric gel formulation to provide sustained release
Implementation Method 5
In the preferred embodiment, viral mediate delivery is used to for the nucleic acids
Data Source
AI summary
Formulations including a nucleic acid such as antisense RNA to modify EGR2 activity, including WD5 and EZH2, so that H3K4me3 is activated and H3K27me3 histone markers are repressed on the promoters of c-JUN and EGR2 have been developed. These are delivered by injection at the site of nerve damage, using a polymeric gel formulation to provide sustained release. In the preferred embodiment, viral mediated delivery is used to for the nucleic acids. The treatment is administered to cause remyelination of the nerves damaged by trauma or diseases such as Charcot-Marie-Tooth Disease (CMT), Guillain-Barre Syndrome (GBS), diabetic neuropathy or chemotherapy induced peripheral neuropathy.